TYO:4534

Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. The company offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatologists, psychiatry, and gastroenterological, including Realda and Collagen for the treatment of ulcerative colitis; Goofis and Movicol for the treatment of chronic constipation; interstitial pulmonary hypertension for the treatment of pulmonary arterial hypertension; Treprospermid, for pulmonary hypertension associated with ulcerative lung disease; Uris, for gout and hyperuricemia; and Clorox, for ulcerative colitis; Epadel for hyperlipidemia and obstructive arteriosclerosis; Treprost for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; Atelec, a calcium channel blocker antihypertensive drug; Heparin Na anticoagulants; and Onboard, ulcerative colitis and Crohn's disease treatment agents. In addition, it develops medical devices, including dMD-002, which is used for the treatment of cavernous nerve injury; and dMD-003 for adhesion prevention material. Further, the company engages in the development, production, distribution, sale, and marketing of skincare products, as well as academic research and marketing. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Shinjuku, Japan.